Company news
Verrica Pharmaceuticals Inc. news in 2022
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2022, newest first.
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 6, 2022
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 10, 2022
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
July 31, 2022
Verrica Announces Proposed Public Offering of Common Stock
June 28, 2022
Verrica Announces Pricing of Public Offering of Common Stock
June 28, 2022
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
June 27, 2022
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
May 23, 2022
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
May 8, 2022
Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
April 6, 2022
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
April 4, 2022
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results
March 1, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 68 slides · Sep 14, 2022
- Investor Presentation (April 2022)
Investor deck · 59 slides · Apr 7, 2022